• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders

    6/23/25 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email

    TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding.

    Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the election of directors are as follows:

    Name of DirectorNumber of Shares Voted ForPercentage of Shares Voted ForNumber of Shares Withheld from VotingPercentage of Shares Withheld from Voting
    Michael Gorenstein206,219,87592.38%17,012,4437.62%
    Jason Adler215,665,94696.61%7,566,3723.39%
    Murray Garnick215,548,31296.56%7,684,0063.44%
    Kamran Khan216,349,69496.92%6,882,6243.08%
    Dominik Meier216,404,34796.94%6,827,9713.06%
    Elizabeth Seegar211,177,23294.60%12,055,0865.40%
    James Rudyk215,956,20396.74%7,276,1153.26%



    Shareholders also approved an advisory (non-binding) resolution on the compensation of the Company's named executive officers, with 94.13% of votes cast in favor of such resolution, and approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2025 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration.

    For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.gov/edgar.

    About Cronos

    Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

    For further information, please contact:

    Harrison Aaron

    Investor Relations

    Tel: (416) 504-0004

    [email protected]



    Primary Logo

    Get the next $CRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    1/27/2022$5.54 → $3.24Underperform → Hold
    Jefferies
    More analyst ratings

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bernstein initiated coverage on Cronos Group with a new price target

      Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

      11/2/22 6:32:18 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Cronos Group from Hold to Buy

      7/28/22 9:01:16 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cronos Group upgraded by CIBC

      CIBC upgraded Cronos Group from Neutral to Sector Outperform

      5/11/22 7:33:42 AM ET
      $CRON
      Medicinal Chemicals and Botanical Products
      Health Care